09:56 AM EST - Oncolytics Biotech Inc. : announced that it has entered into an agreement whereby the NCIC Clinical Trials Group at Queen's University in Kingston, Ontario, will sponsor and conduct a randomized Phase II study of REOLYSIN® in patients with advanced or metastatic breast cancer. Oncolytics Biotech Inc.
shares T.ONC are trading up $0.01 at $3.38.
